| 63.27 2.24 (3.67%) | 10-15 12:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 73.43  |
1-year : | 85.76 |
| Resists | First : | 62.86 |
Second : | 73.43 |
| Pivot price | 57.43 |
|||
| Supports | First : | 53.19 |
Second : | 47.22 |
| MAs | MA(5) : | 60.72 |
MA(20) : | 55.22 |
| MA(100) : | 41.03 |
MA(250) : | 43.66 |
|
| MACD | MACD : | 4 |
Signal : | 3.7 |
| %K %D | K(14,3) : | 93.8 |
D(3) : | 91.4 |
| RSI | RSI(14): 76.4 |
|||
| 52-week | High : | 62.86 | Low : | 29.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CYTK ] has closed below upper band by 18.2%. Bollinger Bands are 86.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 61.6 - 61.98 | 61.98 - 62.33 |
| Low: | 57.99 - 58.41 | 58.41 - 58.82 |
| Close: | 60.36 - 61 | 61 - 61.62 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Wed, 15 Oct 2025
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
Mon, 13 Oct 2025
Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire
Fri, 10 Oct 2025
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK - Sahm
Wed, 08 Oct 2025
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 1.1913e+008 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 13,830 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.376e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -167 % |
| Return on Assets (ttm) | -24.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 26 % |
| Gross Profit (p.s.) | 1051.32 |
| Sales Per Share | 1.26088e+008 |
| EBITDA (p.s.) | -4.48382e+008 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -427 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.84 |
| Dividend | 0 |
| Forward Dividend | 1.411e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|